News FDA starts review of Summit's VEGFxPD-1 bispecific Summit moves ahead in the race to bring a VEGFxPD-(L)1 drug to market, after the FDA started a review of ivonescimab in lung cancer.
News ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer Akeso/Summit's PD-1xVEGF drug ivonescimab bests a PD-1 inhibitor as first-line therapy in Chinese NSCLC patients, but a bigger test is yet to come.
News Mixed data from lung cancer trials on show at WCLC Highlights of the WCLC show include new data for AstraZeneca's Tagrisso, Summit's ivonescimab, MSD/Daiichi's I-DXd, and BMS/Systimmune's iza-bren.
News Summit climbs on rumour of $15bn AstraZeneca interest Is AstraZeneca about to join the ranks of pharma companies spending big bucks on PD(L)-1xVEGF bispecific antibodies for cancer?
News Summit shrugs off survival miss with its VEGF bispecific Summit Therapeutics thinks new data on PD-1xVEGF drug ivonescimab may support FDA approval, despite a survival miss.
News Akeso PD-1 inhibitor cleared as Keytruda challenger advances Akeso has bagged an FDA approval for its PD-1 inhibitor penpulimab and reported new data on highly-touted PD-1/VEGF bispecific ivonescimab.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
